Literature DB >> 25171741

Maternal hookworm modifies risk factors for childhood eczema: results from a birth cohort in Uganda.

Harriet Mpairwe1, Juliet Ndibazza, Emily L Webb, Margaret Nampijja, Lawrence Muhangi, Barbara Apule, Swaib Lule, Hellen Akurut, Dennison Kizito, Mohammed Kakande, Frances M Jones, Colin M Fitzsimmons, Moses Muwanga, Laura C Rodrigues, David W Dunne, Alison M Elliott.   

Abstract

BACKGROUND: Worms may protect against allergy. Early-life worm exposure may be critical, but this has not been fully investigated.
OBJECTIVES: To investigate whether worms in pregnancy and in early childhood are associated with childhood eczema incidence.
METHODS: The Entebbe Mother and Baby Study, an anthelminthic treatment trial, enrolled pregnant women between 2003 and 2005 in Uganda. Mothers were investigated for worms during pregnancy and children annually. Eczema was doctor-diagnosed from birth to age five years. A planned observational analysis was conducted within the trial cohort to investigate associations between worms and eczema.
RESULTS: Data for 2345 live-born children were analysed. Hookworm was the most prevalent maternal worm (45%). Childhood worms were less prevalent. Eczema incidence was 4.68/100 person-years. Maternal hookworm was associated with reduced eczema incidence [adjusted hazard ratio (95% confidence interval), p-value: 0.71(0.51-0.99), 0.04] and modified effects of known risk factors for eczema: Dermatophagoides-specific IgE in children was positively associated with eczema incidence if the mother had no hookworm [2.72(1.11-6.63), 0.03], but not if the mother had hookworm [0.41(0.10-1.69), 0.22], interaction p-value = 0.03. Similar interactions were seen for maternal history of eczema {[2.87(1.31-6.27, 0.008) vs. [0.73(0.23-2.30), 0.60], interaction p-value = 0.05}, female gender {[1.82(1.22-2.73), 0.004 vs. [0.96(0.60-1.53), 0.87], interaction p-value = 0.04} and allergen-specific IgE. Childhood Trichuris trichiura and hookworm were inversely associated with eczema.
CONCLUSIONS: Maternal hookworm modifies effects of known risk factors for eczema. Mechanisms by which early-life worm exposures influence allergy need investigation. Worms or worm products, and intervention during pregnancy have potential for primary prevention of allergy.
© 2014 The Authors. Pediatric Allergy and Immunology Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  IgE; Uganda; birth cohort; children; eczema; effect modification; hookworm; incidence; pregnancy; skin prick test

Mesh:

Substances:

Year:  2014        PMID: 25171741      PMCID: PMC4312885          DOI: 10.1111/pai.12251

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


Allergy is a global problem affecting approximately 20% of the world's population (1) and is on the increase in developing countries, but the causes of this increase are unknown (2). Environmental factors and gene–environment interactions have an important role in the aetiology of allergy (3). Atopy, measured by increased allergen-specific IgE or positive skin prick responses to allergens, is a strong risk factor for allergy in developed countries but reportedly less so in developing countries (4–6). The reasons for this discrepancy are not known, but there is a suggestion that chronic immune-modulating infections such as worms, which are prevalent in developing countries, could play a role (7). Several observational studies have investigated associations between worms and allergy [reviewed by Leonardi-Bee et al. (8) and Flohr et al. (9)]. Results from these studies are inconsistent: some show an inverse association, others a positive association and some no association. There is evidence that prenatal exposure to worms influences later responses to childhood worm infections (10) and possibly to unrelated antigens such as BCG vaccine (11). In this analysis, we investigated whether exposure to worms during pregnancy and in early childhood was associated with eczema incidence in early childhood.

Methods

Study setting

Entebbe Mother and Baby Study (EMaBS) was a trial among pregnant women and their offspring residing in peri-urban, fishing and rural communities beside Lake victoria, Uganda. Details of the trial design are reported elsewhere (12). In summary, EMaBS was a randomized, double-blinded, placebo-controlled trial of anthelminthic treatment in pregnancy using single-dose albendazole (400 mg) or placebo and praziquantel (40 mg/kg) or placebo in a 2 × 2 factorial design. At age fifteen months, the children resulting from these pregnancies were randomized to receive either albendazole or placebo quarterly until age five years (12). The study was approved by the Uganda Virus Research Institute Science and Ethics Committee, the Uganda National Council for Science and Technology, and the London School of Hygiene and Tropical Medicine ethics committee.

Specific objective

The objective of this analysis was to investigate whether worm infections in pregnancy and in early childhood are associated with reduced eczema incidence in the first five years of life.

Study enrolment and follow-up

EMaBS eligibility criteria have been reported elsewhere (12). Eligible pregnant women provided written informed consent prior to enrolment and provided stool and blood samples at enrolment and delivery. At enrolment, a questionnaire was completed, and women underwent testing for asymptomatic malaria and for HIV. Six weeks after delivery, all women received anthelminthic treatment with both albendazole and praziquantel. They were encouraged to bring the children to the study clinic for routine immunisations and for the treatment of illnesses, all free of charge. Children were routinely seen annually, as close to their birthday as possible, to provide stool and blood samples. Worm infections detected at annual visits were treated. Children seen at age three between November 2007 and March 2009 were selected for skin prick tests and allergen-specific IgE testing.

Skin prick tests and allergen-specific IgE

We conducted skin prick testing (SPT) according to standard procedure (13) usingBlomia tropicalis, Dermatophagoides mix, cow's milk and egg white, with histamine and saline controls (ALK Abello, Hoersholm, Denmark). A diameter of ≥3 mm was considered positive. Allergen-specific IgE testing was performed for children who underwent SPT at three years by ELISA, as previously described (14), using Dermatophagoides mix (Dermatophagoides farina andDermatophagoides pteronyssinus) and German cockroach (Blattella germanica) (Greer Labs, Lenoir, NC, USA). Positive sera standardized using the Immunocap Assay System (Phadia, Uppsala, Sweden) were used to standardize the ELISA assay.

Other laboratory procedures

Stool samples were analysed by the Kato-Katz (15) method. Two slides were examined for each sample, read within 30 min for hookworm and the following day for the other worms includingSchistosoma mansoni,Trichuris trichiura andAscaris lumbricoides. We used the charcoal culture method (16) forStrongyloides stercoralis, thick blood smears for malaria infection and the modified Knott's method forMansonella perstans and other microfilariae (17).

Statistical methods

Data were collected on pre-coded case report forms and analysed using stata version 10 (Stata Corp., College Station, TX, USA). The sample size of 2500 pregnant women for the EMaBS trial was planned for infectious disease end-points for the trial interventions (12). Assuming eczema incidence of 5 per 100 person-years, this observational analysis would have over 80% power to detect exposures with a rate ratio of 1.30 or higher, at 5% significance level. This observational analysis was a planned secondary analysis for the trial cohort.

Outcomes and exposures

The primary outcome for this analysis was doctor-diagnosed eczema, defined as a recurrent itchy rash, with either wet weeping skin or dry scaly skin and with a typical distribution (18). Eczema was either a presenting complaint or an incidental finding during routine or other illness visits. Worm infections were the primary exposures of interest. Maternal socio-economic status, education, area of residence and history of allergy were considered as potential confounders for the association between worms and eczema and as exposures of interest in their own right. In addition, children's birth order, birth weight and childhood illnesses were considered as potential confounders for the association between childhood worms and eczema, as well as exposures. Children's atopic status (SPT and allergen-specific IgE) was considered as exposures. For atopy and for other factors that were positively associated with eczema, maternal hookworm was investigated as a potential effect modifier. Effect modification by the trial interventions was also investigated.

Recoding of variables

Principal component analysis was used to identify dominant variables (household items owned, building materials and number of rooms) to create a score that was regrouped as lower vs. higher socio-economic status (19). Area of residence was divided into zones based on topography and the grouping of settlements, which followed geo-referencing of participant's addresses using hand-held global-positioning system receivers (Garmin eTrex) (20). A World Health Organisation (WHO) infection intensity classification was used for hookworm (21). For maternal asymptomatic malaria, results at enrolment and delivery were combined to generate a binary variable for malaria during pregnancy. For childhood illnesses, numbers of episodes of malaria, diarrhoea, lower and upper respiratory tract infection were analysed as continuous variables. Due to the low prevalence of childhood worm infections, data from one to five years were combined into a single binary variable (ever infected or never infected) for each type of worm infection. We used the standard cut-off point (0.35 kUA/l) for allergen-specific IgE to categorize children as atopic or non-atopic.

Regression analysis

We used Cox regression to assess crude and adjusted associations between exposures and eczema incidence, with robust standard errors to allow for clustering of events within each child. The Wald test was used to test for effect modification. For each child, time at risk began at birth and ended either at five years of age, loss to follow-up or death. Factors listed above as potential confounders were included in multivariable models, with the exception of those with substantial missing data and those whose inclusion had no impact on the hazard ratios for other exposures. Analyses for child's gender and atopy were not adjusted as no potential confounders were identified.

Results

Participants' profile

Between April 2003 and November 2005, EMaBS enrolled 2507 pregnant women resulting in 2345 recorded live births. Follow-up of children started from birth of the first child in April 2003 and finished in April 2011, when the last child reached five years. Follow-up time for 116 (5.0%) and 594 (25.3%) of the 2345 live-born children was censored at death or loss to follow-up, respectively, leaving 1635 (69.7%) still in follow-up at age five years (22). The mean number of routine or illness clinic visits per child was 14 (range 0–63). Mothers were mostly of low education status, and worm prevalence was high (68% infected with at least one worm species). Eczema incidence was 10.4/100 person-years of follow-up (pyrs) in infancy (14) and 4.68/100 pyrs in the first five years of life.

Maternal factors associated with childhood eczema

Associations between maternal factors and eczema incidence are shown in Table1. Children from rural areas had significantly less eczema compared with children from urban areas. Maternal history of eczema was strongly associated with childhood eczema. There was a strong association between maternal albendazole and childhood eczema as previously reported (14).
Table 1

Maternal factors and their association with childhood eczema in the first five years of life

Maternal factorNumber of children in each category (%)No of eczema eventsPerson-years at risk (×100)Rate (per 100 pyrs)Crude HR (95% CI)aHR*(95% CI)p-value
Education
 None/primary1278 (55)23251.654.49110.85
 Post-primary1063 (45)22044.634.931.11 (0.84–1.54)0.97 (0.70–1.35)
Household socio-economic status
 Lower status1053 (46)16442.783.83110.08
 Higher status1248 (54)27451.895.281.39 (0.99–1.96)1.36 (0.96–1.92)
Area of residence§
 Entebbe, town950 (41)25138.746.48110.002
 Kiggungu, fishing village261 (11)1811.251.600.25 (0.14–0.43)0.27 (0.15–0.46)
 Manyago and Kabale, peri-urban651 (28)13126.894.870.75 (0.53–1.07)0.76 (0.52–1.10)
 Katabi, rural451 (20)4818.482.600.40 (0.25–0.66)0.42 (0.25–0.68)
Regular cigarette smoking by adult in house
 No1429 (81)32066.184.83110.56
 Yes330 (19)8114.985.411.11 (0.64–1.92)1.17 (0.69–1.99)
Maternal history of asthma
 None1706 (97)38278.664.86110.26
 Yes60 (3)192.846.701.40 (0.73–2.70)1.44 (0.76–2.74)
Maternal history of eczema**
 None1710 (97)37478.944.74110.02
 Yes56 (3)272.5510.592.24 (1.12–4.47)2.28 (1.14–4.53)
Maternal albendazole trial arm during pregnancy
 Placebo arm1175 (50)17548.213.6310.005
 Albendazole arm1170 (50)27748.265.741.58 (1.15–2.17)
Maternal worm infections during pregnancy
 1. Hookworm††: None1311 (56)29854.345.48110.04
 Yes1025 (44)15141.783.610.65 (0.48–0.90)0.71 (0.51–0.99)
 2. M. perstans‡‡: None1841 (79)38975.855.13110.10
 Yes496 (21)6320.323.100.60 (0.39–0.92)0.70 (0.45–1.07)
 3. S. mansoni††: None1915 (82)38178.564.85110.51
 Yes421 (18)6817.553.870.80 (0.55–1.15)0.88 (0.61–1.28)
 4.S. stercoralis§§: None2041 (88)38084.034.52110.33
 Yes283 (12)6511.605.601.23 (0.77–1.95)1.27 (0.78–2.06)
 5.T. trichiura††: None2130 (91)42287.814.81110.59
 Yes206 (9)278.303.250.67 (0.24–1.86)0.73 (0.23–2.33)
 6.A. lumbricoides††: No2282 (98)46693.874.75110.08
 Yes54 (2)32.251.330.28 (0.09–0.87)0.37 (0.12–1.14)
Hookworm category††
 None1311 (56)29854.345.48110.03
 Mild872 (37)13435.703.750.68 (0.49–0.95)0.74 (0.53–1.04)
 Mod-severe153 (7)176.082.790.51 (0.27–0.96)0.56 (0.30–1.07)
Maternal asymptomatic malaria during pregnancy¶¶
 None2037 (88)41484.234.91110.03
 Yes266 (12)3410.643.200.65 (0.41–1.02)0.59 (0.37–0.95)

Pyrs, person years; CI, confidence interval; HR, hazard ratio; aHR, adjusted hazard ratio.

Adjusted for maternal education, area of residence and household socio-economic status.

No of missing variables:

 = 4,

‡ = 44,

 = 32,

 = 586,

 = 579,

 = 579,

 = 9,

 = 8,

 = 21,

 = 42.

Maternal factors and their association with childhood eczema in the first five years of life Pyrs, person years; CI, confidence interval; HR, hazard ratio; aHR, adjusted hazard ratio. Adjusted for maternal education, area of residence and household socio-economic status. No of missing variables: = 4, ‡ = 44, = 32, = 586, = 579, = 579, = 9, = 8, = 21, = 42. Maternal hookworm was inversely associated with eczema incidence, and this association was strongest among those with heavier infections (Table1). In adjusted analyses, maternal infections with other worm species were not associated with childhood eczema. Maternal asymptomatic malaria infection during pregnancy had a strong inverse association with childhood eczema.

Childhood factors associated with childhood eczema

As presented in Table2, neither child's birth order nor birth weight was associated with childhood eczema. Female children had a higher eczema incidence. There was an inverse association between the number of malaria episodes and eczema, but not for diarrhoea, lower or upper respiratory infections. The prevalence of worm infections in the first five years was relatively low. ChildhoodT. trichiura and hookworm were inversely associated with eczema. The remaining worm infections showed either a weak inverse association or no association with eczema.
Table 2

Childhood factors associated with eczema in the first five years of life

Childhood factorNumber of children in each category (%)No of eczema eventsPerson-years at risk (×100)Rate (per 100 pyrs)Crude HR (95% CI)aHR (95% CI)p-value*
Child's birth order
 First born622 (27)10824.254.45110.06
 2nd–4th born1342 (57)25755.914.601.05 (0.72–1.53)1.07 (0.73–1.58)
 5th born or more381 (16)8716.315.331.22 (0.73–2.05)1.37 (0.82–2.27)
Child's birth weight
 Normal1719 (90)36871.705.13110.48
 Low (≤2.5 kg)187 (10)317.504.130.81 (0.43–1.51)0.79 (0.41–1.51)
Child's sex
 Male1208 (52)19349.753.8810.03
 Female1135 (48)25946.725.541.43 (1.04–1.97)
Common childhood infections diagnosed prospectively (0–5 yr)
1. Malaria
 Mean (range) of episodes: 1.4 (0–16)0.94 (0.88–1.00)0.88 (0.83–0.94)<0.0001
2. Diarrhoea
 Mean (range) of episodes: 2.6 (0–22)1.10 (1.05–1.16)1.02 (0.93–1.10)0.71
3. Lower respiratory infections
 Mean (range) of episodes: 0.4 (0–9)1.25 (1.11–1.41)1.10 (0.96–1.26)0.18
4. Upper respiratory infections
 Mean (range) of episodes: 11 (0–58)1.04 (1.03–1.06)1.00 (0.95–1.04)0.92
Childhood worm infections (assessed annually from 1 to 5 yr)
 1.T. trichiura (810):None643 (79)17932.085.58110.002
 Yes167 (21)168.131.970.35 (0.18–0.66)0.35 (0.18–0.67)
 2.A. lumbricoides (765): None680 (89)18033.935.30110.22
 Yes85 (11)124.112.920.54 (0.28–1.06)0.64 (0.32–1.30)
 3. S. mansoni (756): None700 (93)17734.935.07110.45
 Yes56 (7)142.705.191.00 (0.34–2.97)1.55 (0.50–4.81)
 4. Hookworm (747): None705 (94)18535.185.26110.05
 Yes42 (6)41.992.010.37 (0.14–0.98)0.33 (0.11–1.02)
 5.M. perstans (864): None839 (97)20641.874.92110.28
 Yes25 (3)91.147.861.54 (0.66–3.59)1.60 (0.68–3.77)
Child's atopic status (assessed at 3 yr)§
Skin prick responses (569)
 Negative464 (82)6722.712.951<0.0001
 Positive105 (18)495.089.653.26 (1.84–5.80)
Dermatophagoides-specific IgE (540)
 Non-atopic478 (89)9323.343.9810.21
 Atopic62 (11)203.026.621.66 (0.75–3.69)
Cockroach-specific IgE (540)
 Non-atopic448 (83)9121.904.1510.67
 Atopic92 (17)224.464.941.18 (0.55–2.55)

Pyrs, person years; CI, confidence interval; HR, hazard ratio; aHR, adjusted hazard ratio.

For categorical variables, this is the p-value for the test of trend.

Adjusted for maternal education, area of residence and household socio-economic status; childhood illnesses were additionally adjusted for the total number of clinic visits a child made during the study period. Breastfeeding was not adjusted for as 98% of the children in this study were breastfed.

Children with data on worm infections at all five annual visits were included for this analysis.

Three-year-old children seen between November 2007 and March 2009 were selected for skin prick tests (4 allergens) and allergen-specific IgE testing.

No of missing variables:

 = 430,

 = 2.

Childhood factors associated with eczema in the first five years of life Pyrs, person years; CI, confidence interval; HR, hazard ratio; aHR, adjusted hazard ratio. For categorical variables, this is the p-value for the test of trend. Adjusted for maternal education, area of residence and household socio-economic status; childhood illnesses were additionally adjusted for the total number of clinic visits a child made during the study period. Breastfeeding was not adjusted for as 98% of the children in this study were breastfed. Children with data on worm infections at all five annual visits were included for this analysis. Three-year-old children seen between November 2007 and March 2009 were selected for skin prick tests (4 allergens) and allergen-specific IgE testing. No of missing variables: = 430, = 2. Three-year-old children with a positive skin prick test (to any of the four allergens) had a higher incidence of eczema. Positive allergen-specific IgE responses to Dermatophagoides mix, and German cockroach allergens showed no overall association with eczema.

Effect modification of maternal hookworm on risk factors associated with eczema

To understand why the association between atopy and allergy is weak in developing countries, we examined the role of worms as potential effect modifiers. We investigated whether hookworm, the most prevalent maternal worm, modified the effects of atopy and other risk factors positively associated with eczema in this analysis (Table3). We found a strong positive association between maternal history of eczema and childhood eczema among children whose mothers had no hookworm infection during pregnancy, but not among children whose mothers were infected with hookworm (interaction p-value 0.05), despite similarities in the prevalence of history of eczema among mothers with or without hookworm. Similar trends towards effect modification by hookworm were observed for associations between eczema and maternal albendazole treatment during pregnancy and between eczema and skin prick test responses in the children, but these were not statistically significant. Female children had a higher eczema incidence if their mothers had no hookworm, but not if they had hookworm (interaction p-value 0.04). Dermatophagoides mix-specific IgE showed a strong positive association with eczema among the children whose mothers had no hookworm during pregnancy, but not among children whose mothers had hookworm (interaction p-value 0.03). Cockroach-specific IgE had a weak positive association with eczema among children whose mothers had no hookworm, but a weak inverse association among children whose mothers had hookworm (interaction p-value 0.01). Less prevalent maternal worm infections showed a similar trend to that of hookworm but power to detect effect modification was low (results not shown).
Table 3

The interaction of maternal hookworm infection during pregnancy with the other risk factors for eczema in the first five years of life

Maternal hookworm statusNumber (%) with given risk factorNo. of eczema eventsPerson years at risk (×100)Rate (per 100 pyrs)Crude HR (95% CI)aHR* (95% CI)p-valueTest for interaction p-value
Maternal history of eczema (1766)
 NoneNo 955 (96)24044.335.41110.0080.05
Yes 35 (4)241.6014.962.78 (1.29–6.00)2.87 (1.31–6.27)
 YesNo 751 (97)13134.423.81110.60
Yes 21 (3)30.953.170.83 (0.28–2.42)0.73 (0.23–2.30)
Maternal albendazole during pregnancy (2345)
 NonePlacebo 643(49)10326.653.8610.0060.15
Albendazole 668 (51)19527.687.041.82 (1.19–2.79)
 YesPlacebo 528 (52)7221.413.3610.56
Albendazole 497 (48)7920.373.881.15 (0.72–1.83)
Child's gender (2334)
 NoneMale 695 (53)11328.463.9710.0040.04
Female 614 (47)18525.877.151.82 (1.22–2.73)
 YesMale 506 (49)7720.943.6810.87
Female 519 (51)7420.843.550.96 (0.60–1.53)
Child's skin prick test positive responses (569)
 NoneNegative 264 (79)2812.932.161<0.00010.18
Positive 70 (21)353.4110.274.74 (2.30–9.73)
 YesNegative 199 (85)379.733.8010.08
Positive 35 (15)141.678.372.20 (0.92–5.26)
Child's dermatophagoides mix-specific IgE responses (539)
 NoneNon-atopic 276 (87)4513.503.3310.030.03
Atopic 41 (13)181.989.072.72 (1.11–6.63)
 YesNon-atopic 201 (91)469.794.7010.22
Atopic 21 (9)21.041.930.41 (0.10–1.69)
Child's German cockroach-specific IgE responses (539)
 NoneNon-atopic 258 (81)4312.643.4010.100.01
Atopic 59 (19)202.847.042.06 (0.87–4.85)
 YesNon-atopic 189 (85)469.214.9910.06
Atopic 33 (15)21.621.240.25 (0.06–1.04)

Pyrs, person years; CI, confidence interval; HR, hazard ratio; aHR, adjusted hazard ratio.

Adjusted for maternal education, area of residence and household socio-economic status.

Three-year-old children seen between November 2007 and March 2009 were selected for r skin prick tests (4 allergens) and allergen-specific IgE testing.

The interaction of maternal hookworm infection during pregnancy with the other risk factors for eczema in the first five years of life Pyrs, person years; CI, confidence interval; HR, hazard ratio; aHR, adjusted hazard ratio. Adjusted for maternal education, area of residence and household socio-economic status. Three-year-old children seen between November 2007 and March 2009 were selected for r skin prick tests (4 allergens) and allergen-specific IgE testing.

Effect of trial anthelminthic drugs on the association between worms and eczema

We found a strong inverse association between maternal hookworm and eczema if the mother received albendazole [aHR (95% CI) 0.57 (0.37–0.90)] that was not present if the mother received albendazole placebo [0.99 (0.62–1.60)], although this interaction was not significant (p-value 0.13). The association between childhood hookworm (andT. trichiura) and eczema was not influenced by the three-monthly albendazole/placebo that the children were randomized to receive.

Discussion

This is the first study to show that maternal hookworm infection is inversely associated with eczema incidence and modifies effects of known risk factors for childhood eczema such as mother's history of eczema, child's gender and atopic status. We also found that early childhood hookworm andT. trichiura, although of low prevalence, were associated with a reduced incidence of eczema. It is important to note that most eczema episodes occurred in infancy, before most children acquired any worm infections, suggesting that the observed inverse association is not causal but may be due to other environmental exposures or to a genetic predisposition – such that children predisposed to eczema might be less susceptible to worm infections. The study had a number of limitations. First, worm infections were determined by the Kato Katz method using a single stool sample, which is relatively insensitive (23). Secondly, confounding is an inherent flaw of cohort studies, and it is possible that there are unmeasured confounders. Thirdly, clinicians were not blinded to the worm status of the participants, which may have led to observer bias. However, this is unlikely to have affected the antibody results as immunology technicians were unaware of the worm status of the participants. Lastly, we tested only a sample of children for atopy. This reduced power of the study, particularly for interaction analyses. Our findings are generalisable to other communities in developing countries with high prevalence but low intensity of hookworm infections. Other studies have investigated possible modifying effects of worms on the association between atopy and allergy and obtained results similar to ours. A case–control study in Ecuador found that the association between atopy and wheeze was stronger among uninfected children compared with those with geohelminths (24). A study among Cuban children found a strong positive association between atopy and physician-diagnosed asthma among children without Toxocara antibodies, but a weak association among those with Toxocara antibodies (25). This evidence suggests that worm infections may, at least in part, explain why atopy is weakly associated with clinical allergy in developing countries, in contrast to the strong associations reported in developed countries. The finding of an inverse association between malaria and eczema was unexpected but was consistent for asymptomatic malaria in pregnancy and for clinical malaria illnesses in early childhood. Malaria is a potent immune modulator which can influence the response to unrelated antigens (26). The observation that children from rural areas were at reduced risk of eczema compared with their counterparts from urban areas has also been observed in other developing countries (27,28). This difference remained even after adjusting for worms and potential confounders. What is intriguing is that these urban/rural areas are located within the same district, a relatively small geographical area. Perhaps, multiple infections, or exposure to farm animals or other aspects of rural life, whose effect was not measured in this analysis, might explain these urban/rural differences. This study has important implications for future research. First, there is urgent need to understand the underlying immune mechanisms by which hookworm could modify the effects of known risk factors for eczema. Such studies may take the form of clinical trials of worms for therapy or worm products. Indeed, early phase clinical trials, using iatrogenic hookworm, have been initiated in the United Kingdom (29,30). With careful attention to design, studies in developing countries can be useful as the effects of interventions for worm control on allergy are explored. Secondly, pregnancy and early childhood provide a window of opportunity during which interventions for the primary prevention of allergy could be targeted.

Conclusion

We have demonstrated that prenatal hookworm exposure modifies the effects of known risk factors for childhood eczema and that early childhood worms are associated with reduced eczema incidence. More research is needed to understand possible underlying immune mechanisms and to explore the therapeutic potential of worms or their products, particularly during pregnancy or early childhood, in the primary prevention of allergy.
  26 in total

1.  Relative contribution of day-to-day and intra-specimen variation in faecal egg counts of Schistosoma mansoni before and after treatment with praziquantel.

Authors:  J Utzinger; M Booth; E K N'Goran; I Müller; M Tanner; C Lengeler
Journal:  Parasitology       Date:  2001-05       Impact factor: 3.234

2.  Urban-rural differences in questionnaire-derived markers of asthma in Kenyan school children.

Authors:  J A Odhiambo; L W Ng'ang'a; M W Mungai; C M Gicheha; J K Nyamwaya; F Karimi; P T Macklem; M R Becklake
Journal:  Eur Respir J       Date:  1998-11       Impact factor: 16.671

3.  Helminth- and Bacillus Calmette-Guérin-induced immunity in children sensitized in utero to filariasis and schistosomiasis.

Authors:  I Malhotra; P Mungai; A Wamachi; J Kioko; J H Ouma; J W Kazura; C L King
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

4.  Atopic sensitization and the international variation of asthma symptom prevalence in children.

Authors:  Gudrun Weinmayr; Stephan K Weiland; Bengt Björkstén; Bert Brunekreef; Gisela Büchele; William O C Cookson; Luis Garcia-Marcos; Maia Gotua; Christina Gratziou; Marianne van Hage; Erika von Mutius; Mall-Anne Riikjärv; Peter Rzehak; Renato T Stein; David P Strachan; John Tsanakas; Kristin Wickens; Gary W Wong
Journal:  Am J Respir Crit Care Med       Date:  2007-06-15       Impact factor: 21.405

5.  Wheezing, allergy, and parasite infection in children in urban and rural Ethiopia.

Authors:  Damtew Dagoye; Zegaye Bekele; Kifle Woldemichael; Hailu Nida; Meselech Yimam; Andy Hall; Andrea J Venn; John R Britton; Richard Hubbard; Sarah A Lewis
Journal:  Am J Respir Crit Care Med       Date:  2003-01-24       Impact factor: 21.405

6.  The impact of helminths on the response to immunization and on the incidence of infection and disease in childhood in Uganda: design of a randomized, double-blind, placebo-controlled, factorial trial of deworming interventions delivered in pregnancy and early childhood [ISRCTN32849447].

Authors:  Alison M Elliott; Moses Kizza; Maria A Quigley; Juliet Ndibazza; Margaret Nampijja; Lawrence Muhangi; Linda Morison; Proscovia B Namujju; Moses Muwanga; Narcis Kabatereine; James A G Whitworth
Journal:  Clin Trials       Date:  2007       Impact factor: 2.486

7.  Toxocara seropositivity, atopy and asthma: a study in Cuban schoolchildren.

Authors:  K Kanobana; K Vereecken; R Junco Diaz; I Sariego; L Rojas; M Bonet Gorbea; K Polman
Journal:  Trop Med Int Health       Date:  2013-02-08       Impact factor: 2.622

8.  Plasmodium falciparum and helminth coinfection in a semi urban population of pregnant women in Uganda.

Authors:  Stephen D Hillier; Mark Booth; Lawrence Muhangi; Peter Nkurunziza; Macklyn Khihembo; Muhammad Kakande; Moses Sewankambo; Robert Kizindo; Moses Kizza; Moses Muwanga; Alison M Elliott
Journal:  J Infect Dis       Date:  2008-09-15       Impact factor: 5.226

9.  Anthelminthic treatment during pregnancy is associated with increased risk of infantile eczema: randomised-controlled trial results.

Authors:  Harriet Mpairwe; Emily L Webb; Lawrence Muhangi; Juliet Ndibazza; Denise Akishule; Margaret Nampijja; Sophy Ngom-wegi; Josephine Tumusime; Frances M Jones; Colin Fitzsimmons; David W Dunne; Moses Muwanga; Laura C Rodrigues; Alison M Elliott
Journal:  Pediatr Allergy Immunol       Date:  2011-01-23       Impact factor: 6.377

10.  Experimental hookworm infection: a randomized placebo-controlled trial in asthma.

Authors:  J R Feary; A J Venn; K Mortimer; A P Brown; D Hooi; F H Falcone; D I Pritchard; J R Britton
Journal:  Clin Exp Allergy       Date:  2009-12-16       Impact factor: 5.018

View more
  20 in total

1.  Effect of Early-Life Geohelminth Infections on the Development of Wheezing at 5 Years of Age.

Authors:  Philip J Cooper; Martha E Chico; Maritza G Vaca; Carlos A Sandoval; Sofia Loor; Leila D Amorim; Laura C Rodrigues; Mauricio L Barreto; David P Strachan
Journal:  Am J Respir Crit Care Med       Date:  2018-02-01       Impact factor: 21.405

2.  Update on prevention and treatment of intestinal helminth infections.

Authors:  Paul Blair; David Diemert
Journal:  Curr Infect Dis Rep       Date:  2015-03       Impact factor: 3.725

3.  Hookworm Infection among Pregnant Women at First Antenatal Visit in Lira, Uganda: A Cross-Sectional Study.

Authors:  Felister Apili; Stephen Ochaya; Charles Peter Osingada; Scovia Nalugo Mbalinda; David Mukunya; Grace Ndeezi; James K Tumwine
Journal:  Int J Reprod Med       Date:  2020-06-26

4.  The Medical Research Council (UK)/Uganda Virus Research Institute Uganda Research Unit on AIDS--'25 years of research through partnerships'.

Authors:  P Kaleebu; A Kamali; J Seeley; A M Elliott; E Katongole-Mbidde
Journal:  Trop Med Int Health       Date:  2014-10-29       Impact factor: 2.622

5.  Helminths are positively associated with atopy and wheeze in Ugandan fishing communities: results from a cross-sectional survey.

Authors:  E L Webb; M Nampijja; J Kaweesa; R Kizindo; M Namutebi; E Nakazibwe; G Oduru; P Kabubi; J Kabagenyi; G Nkurunungi; D Kizito; L Muhangi; M Akello; J J Verweij; B Nerima; E Tukahebwa; A M Elliott
Journal:  Allergy       Date:  2016-05-20       Impact factor: 13.146

6.  Schistosoma mansoni-specific immune responses and allergy in Uganda.

Authors:  G Nkurunungi; J Kabagenyi; M Nampijja; R E Sanya; B Walusimbi; J Nassuuna; E L Webb; A M Elliott
Journal:  Parasite Immunol       Date:  2017-12-15       Impact factor: 2.280

Review 7.  A life without worms.

Authors:  Richard E Sanya; Gyaviira Nkurunungi; Irene Andia Biraro; Harriet Mpairwe; Alison M Elliott
Journal:  Trans R Soc Trop Med Hyg       Date:  2017-01-01       Impact factor: 2.184

8.  Life-course of atopy and allergy-related disease events in tropical sub-Saharan Africa: A birth cohort study.

Authors:  Swaib A Lule; Harriet Mpairwe; Margaret Nampijja; Florence Akello; Joyce Kabagenyi; Benigna Namara; Gyaviira Nkurunungi; Dennison Kizito; Joseph Kahwa; Lawrence Muhangi; Stephen Nash; Moses Muwanga; Emily L Webb; Alison M Elliott
Journal:  Pediatr Allergy Immunol       Date:  2017-06       Impact factor: 6.377

9.  Effects of treating helminths during pregnancy and early childhood on risk of allergy-related outcomes: Follow-up of a randomized controlled trial.

Authors:  Benigna Namara; Stephen Nash; Swaib A Lule; Hellen Akurut; Harriet Mpairwe; Florence Akello; Josephine Tumusiime; Moses Kizza; Joyce Kabagenyi; Gyaviira Nkurunungi; Lawrence Muhangi; Emily L Webb; Moses Muwanga; Alison M Elliott
Journal:  Pediatr Allergy Immunol       Date:  2017-10-05       Impact factor: 6.377

10.  Career development for infection and immunity research in Uganda: a decade of experience from the Makerere University - Uganda Virus Research Institute research and training programme.

Authors:  Damalie Nakanjako; Flavia Zalwango; Pamela Wairagala; Fiona Luboga; Irene Andia Biraro; Victoria Diana Bukirwa; Mary Gorrethy Mboowa; Steve Cose; Janet Seeley; Alison Elliott
Journal:  AAS Open Res       Date:  2020-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.